Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Recommendation of “Moderate Buy” by Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned an average recommendation of “Moderate Buy” from the twenty-eight research firms that are covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $794.6957.

REGN has been the topic of several recent research reports. Evercore ISI upped their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Canaccord Genuity Group upped their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Citigroup raised their target price on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, BMO Capital Markets lifted their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research report on Thursday, December 4th.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 8,431 shares of company stock valued at $5,733,521. Corporate insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the business. Meyer Handelman Co. grew its holdings in Regeneron Pharmaceuticals by 0.6% in the fourth quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock valued at $2,221,000 after purchasing an additional 18 shares during the period. Marino Stram & Associates LLC lifted its position in shares of Regeneron Pharmaceuticals by 5.3% during the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 20 shares in the last quarter. CoreCap Advisors LLC grew its stake in Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after acquiring an additional 20 shares during the period. Strait & Sound Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals by 3.5% in the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 21 shares in the last quarter. Finally, Parkside Financial Bank & Trust raised its position in Regeneron Pharmaceuticals by 14.8% during the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 21 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $755.51 on Friday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11. The firm has a 50 day moving average of $754.18 and a two-hundred day moving average of $641.57. The firm has a market capitalization of $79.40 billion, a PE ratio of 18.09, a P/E/G ratio of 1.95 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the prior year, the firm earned $12.46 EPS. On average, analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.